Dave Marek, Myovant CEO
April 12, 2022 09:04 AM EDTUpdated 12:28 PM
R&D
FDA+

My­ovant and Pfiz­er’s path to se­cur­ing a sec­ond nod for Myfem­bree gets hazy — and in­vestors re­act quick­ly  

Kyle LaHucik

Senior Reporter

My­ovant was on tap for a May 6 de­ci­sion on a sup­ple­men­tal NDA for its three-in-one pill Myfem­bree, aim­ing to treat mod­er­ate to se­vere pain …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times